Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.

Hepatobiliary & pancreatic diseases international : HBPD INT - 1 Feb 2006

Zhang Wan-Xing, Lai Vincent, Mutimer David, Mirza Darius

Abstract excerpt

BACKGROUND: The recurrence of chronic hepatitis B after liver transplantation results in increased risk for graft failure and death of patients. Lamivudine has been shown to be effective in the treatment of chronic hepatitis B, but resistance to this agent is common after prolonged administration. METHODS: One patient with chronic hepatitis B virus (HBV) infection developed resistance to lamivudine after 15...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Hepatitis, Autoimmune
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lamivudine

Share to Liver Transplantation

Share to Organophosphonates

Share to Recurrence

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 16481305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.PMID 16481305Read ↗

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.Semantic proximity Read ↗

Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.Semantic proximity Read ↗

Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection.Semantic proximity Read ↗

Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience.Semantic proximity Read ↗

[Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients].Semantic proximity Read ↗

Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.Semantic proximity Read ↗

[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].Semantic proximity Read ↗

Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine.Semantic proximity Read ↗

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.Semantic proximity Read ↗

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.Semantic proximity Read ↗

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.Semantic proximity Read ↗

Virologic response and resistance to adefovir in patients with chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.